Our Life Sciences group is a multi-disciplinary team of more than 90 lawyers drawn from across our global network.
We have a reputation for far-sighted advice to some of the world’s leading life science companies and are described as "an efficient and client-oriented team" in Chambers Global 2010 Life Sciences edition.
Our support for pharmaceuticals, biotech, medical devices, nursing homes and other healthcare-related companies, as well as financial institutions operating in the sector, covers the spectrum: mergers and acquisitions (M&A), commercial transactions, including licensing and collaborations, intellectual property (IP) protection and patent disputes, capital markets and finance, regulatory and private equity.
Our international network enables us to deploy the skills of market-leading experts in a number of jurisdictions and we are well placed to advise on cross-border work, both contentious and non-contentious.
News & insights
Publications: 20 January 2022
On 19 January 2022, the Unified Patent Court (UPC) came to life as an international organisation. Now, the preparatory phase for the official start of the UPC system can begin.
News: 03 December 2021
Allen & Overy has advised Vision Healthcare, a Belgium-based consumer healthcare company with a large portfolio of self-care brands and over-the-counter products in several European countries, on the…
Publications: 09 July 2021
As an international treaty the Agreement on a Unified Patent Court (UPCA) provides for the establishment of the Unified Patent Court (UPC). As a joint Court of the Contracting Member States, the UPC…
Publications: 19 April 2021
After weeks of tough wrangling, the Federal Cabinet has decided to oblige companies throughout Germany to offer coronavirus tests to their employees. This obligation will be included in the SARS-CoV-2…